Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TNKS | O95271 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11895074 | 0.85 | CNR2 (0.53) | CCR1ELANELMNANOTUMMEN1 | |
| SCHEMBL5757801 | 0.85 | ELANE (0.56) | CCR1P2RX7ELANELMNATRPV1 | |
| SCHEMBL4024102 | 0.84 | CCR1 (0.45) | CCR1P2RX7ELANENOTUMTP53 | |
| SCHEMBL4024127 | 0.82 | ESRRG (0.47) | CCR1ELANELMNANOTUMMEN1 | |
| SCHEMBL11895081 | 0.82 | ELANE (0.42) | CCR1P2RX7ELANELMNANOTUM | |
| SCHEMBL4022479 | 0.82 | TRPV1 (0.52) | LMNATRPV1MEN1KMT2AMAPT | |
| SCHEMBL4024041 | 0.81 | CCR1 (0.54) | CCR1ELANELMNANOTUMMEN1 | |
| SCHEMBL4023306 | 0.80 | FLT1 (0.47) | ELANELMNATRPV1TDP1MAPT | |
| SCHEMBL4022341 | 0.80 | ELANE (0.51) | ELANEMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL4026336 | 0.80 | ELANE (0.47) | ELANELMNANOTUMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11559520-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | AVALYN PHARMA INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-20210069165-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-10092552-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | AVALYN PHARMA INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170224706-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | GENOA PHARMACEUTICALS, INC. | 2017-08-10 | — | — | US | disclosed |
| US-20120192861-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | GENOA PHARMACEUTICALS, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| EP-1663974-B1 | 2-PYRIDONE DERIVATIVES AS NETROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2009-01-14 | — | — | EP | disclosed |
| US-20070043036-A1 | 2-Pyridone derivatives as neutrophil elastase inhibitors and their use | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
| EP-1663974-A1 | 2-PYRIDONE DERIVATIVES AS NETROPHIL ELASTASE INHIBITORS AND THEIR USE | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026124-A1 | 2-PYRIDONE DERIVATIVES AS NETROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210069165-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | CCR1 1988/4885P2RX7 362/4885ELANE 1574/4885 |
| US-20070043036-A1 | 2-Pyridone derivatives as neutrophil elastase inhibitors and their use | SERPINB1, ELANE, SERPINE1 | CCR1 211/4885P2RX7 555/4885ELANE 2/4885 |
| US-11559520-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | PLPBP, PIR, PDXK | CCR1 1988/4885P2RX7 362/4885ELANE 1574/4885 |
| US-20120192861-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | CCR1 1988/4885P2RX7 362/4885ELANE 1574/4885 |
| US-20170224706-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | CCR1 1988/4885P2RX7 362/4885ELANE 1574/4885 |
| US-10092552-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | PLPBP, PIR, PDXK | CCR1 1988/4885P2RX7 362/4885ELANE 1574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.